<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697463</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC6871</org_study_id>
    <nct_id>NCT00697463</nct_id>
  </id_info>
  <brief_title>Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women</brief_title>
  <acronym>IOPForteo</acronym>
  <official_title>Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young
      individuals sustain one or more low-trauma fractures. Teriparatide [PTH(1-34)], which is FDA
      approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating
      bone formation. The investigators hypothesize that teriparatide will significantly increase
      bone density (BMD) and improve bone structure in premenopausal women with IOP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young
      individuals sustain one or more low-trauma fractures. In studies of IOP in men,
      histomorphometric indices of bone formation are depressed, and affected men respond to
      PTH(1-34) with robust increases in lumbar spine (LS) bone mineral density (BMD). This is the
      beginning of the third year of an R01 (AR4989603) investigating the etiology and
      pathogenesis, as well as the histomorphometric and bone microarchitectural features of IOP in
      premenopausal women. There is evidence of markedly decreased bone formation and
      microarchitectural deterioration with decreased mechanical competence/strength.

      Teriparatide [PTH(1-34)] is an anabolic agent that stimulates bone formation and improves
      bone microarchitecture. Based on findings, the investigators hypothesize that teriparatide
      will significantly increase BMD and improve microarchitecture in premenopausal women with
      IOP.

      This is an open-label study of carefully characterized premenopausal women with IOP who are
      participating in a NIH-funded study and who have fragility fractures or very low bone
      density. Participants in the study will receive 18-24 months of teriparatide and the effects
      on BMD and microstructure, bone mechanical competence, and bone turnover will be assessed. In
      order to assess whether teriparatide stimulates bone formation to the same extent in women
      with IOP as it does in normal women, the study will compare the short-term changes (2 and 4
      weeks) in biochemical markers of bone formation in response to teriparatide between women
      with IOP and normal women who are participating in another NIH-funded study as controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2008</start_date>
  <completion_date type="Actual">January 3, 2012</completion_date>
  <primary_completion_date type="Actual">January 3, 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>Baseline, Month 18 or 24 reported</time_frame>
    <description>Areal BMD at the lumbar spine was measured by dual energy x-ray absorptiometry (DXA) at baseline and at 6, 12, 18, and 24 months, if possible.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Menopause</condition>
  <condition>Fracture</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Women with Idiopathic osteoporosis (IOP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide (PTH 1-34)</intervention_name>
    <description>20 micrograms subcutaneous injection daily</description>
    <arm_group_label>Women with Idiopathic osteoporosis (IOP)</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women of all races.

          -  Ages 20 to 48.

          -  Regular menses (at least 8 periods in the last 12 months).

          -  FSH &lt; 20 mIU/ml during the early follicular phase, to exclude women in the
             perimenopause.

          -  Fracture subjects: documented low trauma fracture(s) at age &gt;= 18 (e.g., fracture
             associated with a fall from a standing height or less).

          -  Low BMD subjects: DXA BMD T score less than or equal to 2.5 at the LS, total hip,
             femoral neck or distal radius, who have not had a fracture.

          -  Control subjects: DXA BMD T score greater than or equal to 1.0 at the LS, total hip,
             femoral neck and distal radius, who have not had a fracture.

          -  All subjects must use appropriate birth control methods to prevent pregnancy for the
             duration of teriparatide treatment.

        Exclusion Criteria:

          -  Secondary Causes of Osteoporosis.

          -  Disorders of mineral metabolism: primary or secondary hyperparathyroidism (serum
             intact PTH &gt; 65 pg/ml), vitamin D deficiency (serum 25OHD &lt; 30 ng/ml), hypercalciuria
             (&gt;300 mg/g creatinine), Paget's disease, clinical osteomalacia, osteogenesis
             imperfecta (OI).

          -  Recent pregnancy or lactation (within past year).

          -  Prolonged amenorrhea (&gt; 6 months) during reproductive years (except during pregnancy
             or lactation).

          -  History of anorexia nervosa.

          -  Malignancy, except cured basal or squamous cell skin carcinoma.

          -  Endocrinopathy: hyperthyroidism (elevated serum thyroxine and/or suppressed TSH),
             untreated hypothyroidism, Cushing's syndrome, prolactin-secreting pituitary adenoma.

          -  Renal insufficiency (serum creatinine above upper limit of female normal range).

          -  Liver disease (AST, ALT, bilirubin, total alkaline phosphatase activity above upper
             normal limit).

          -  Intestinal disorders (celiac disease, pancreatic insufficiency, inflammatory bowel
             disease).

          -  History or current use of glucocorticoids, anticonvulsants, anticoagulants, diuretics,
             methotrexate.

          -  Current use of depot preparations of progesterone or GnRH agonists.

          -  Current use of drug therapies for osteoporosis (estrogen preparations other than
             contraceptives, raloxifene, bisphosphonates, calcitonin, PTH). Subjects who agree to
             discontinue use of these medications will be eligible to participate 6 months after
             discontinuing raloxifene or calcitonin, and 12 months after discontinuing
             bisphosphonates. Total exposure to bisphosphonates must be &lt; 1 year. Subjects who have
             taken PTH at any time in the past will not be eligible.

          -  Additional contraindications to teriparatide use: Unexplained elevated total or bone
             specific alkaline phosphatase or prior external beam or implant radiation therapy
             involving the skeleton.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adi Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <results_first_submitted>January 31, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2018</results_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine, Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Teriparatide</keyword>
  <keyword>Forteo</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Fracture</keyword>
  <keyword>Low Bone Density</keyword>
  <keyword>Premenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Premenopausal women, aged 20-48, with documented adult low trauma fractures or low aBMD by DXA; T score&lt;-2.5 or Z score&lt;-2.0 at the spine or hip and no history of adult low trauma fracture, were recruited at Columbia University Medical Center, NY and Creighton University, NE by advertisement, self- or physician referral.</recruitment_details>
      <pre_assignment_details>No pre-assignment details to report</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Women With Idiopathic Osteoporosis (IOP)</title>
          <description>Each subject will receive 20 micrograms of teriparatide subcutaneously daily.
Teriparatide (PTH 1-34): 20 micrograms subcutaneous injection daily for 18- 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Women With Idiopathic Osteoporosis (IOP)</title>
          <description>Each subject will receive 20 micrograms of teriparatide subcutaneously daily.
Teriparatide (PTH 1-34): 20 micrograms subcutaneous injection daily for 18-24 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA)</title>
        <description>Areal BMD at the lumbar spine was measured by dual energy x-ray absorptiometry (DXA) at baseline and at 6, 12, 18, and 24 months, if possible.</description>
        <time_frame>Baseline, Month 18 or 24 reported</time_frame>
        <population>Of 22 women with IOP who enrolled, one withdrew for personal reasons, therefore the overall number of participants analyzed is 21. The percentage of BMD change is calculated for each participant between baseline and Month 24 or between baseline and Month 18, whichever is the longer reported timeframe as some are lost to follow up by Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Women With Idiopathic Osteoporosis (IOP)</title>
            <description>Each subject will receive 20 micrograms of teriparatide subcutaneously daily.
Teriparatide (PTH 1-34): 20 micrograms subcutaneous injection daily for 18-24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA)</title>
          <description>Areal BMD at the lumbar spine was measured by dual energy x-ray absorptiometry (DXA) at baseline and at 6, 12, 18, and 24 months, if possible.</description>
          <population>Of 22 women with IOP who enrolled, one withdrew for personal reasons, therefore the overall number of participants analyzed is 21. The percentage of BMD change is calculated for each participant between baseline and Month 24 or between baseline and Month 18, whichever is the longer reported timeframe as some are lost to follow up by Month 24.</population>
          <units>percentage of BMD change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed through study completion.</time_frame>
      <desc>The definition of adverse event and/or serious adverse event used to collect adverse event information is the same.</desc>
      <group_list>
        <group group_id="E1">
          <title>Women With Idiopathic Osteoporosis (IOP)</title>
          <description>Each subject will receive 20 micrograms of teriparatide subcutaneously daily.
Teriparatide (PTH 1-34): 20 micrograms subcutaneous injection daily for 18-24 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>One participant had a single episode of hypercalcemia (serum calcium &gt; 10.2 mg/dL) that resolved after per protocol reduction of calcium supplements.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Distal radius fracture</sub_title>
                <description>One participant sustained a distal radius fracture after falling from a stool during the second 12 months.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <description>6 participants had 7 episodes of hypercalciuria (.300 mg/g creatinine) that resolved after per protocol reduction of calcium supplements.</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Without an untreated control group, we cannot attribute the observed effects to teriparatide with certainty. The effects of teriparatide on fractures could not be evaluated. Six women received teriparatide for 18 months rather than for 24 months.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elizabeth Shane, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-7225</phone>
      <email>es54@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

